Profound Medical Reports 86% Year-over-Year Revenue Growth in Q3 2026
Profound Medical (PROF) reported strong third-quarter financial results for 2026, highlighted by an 86% year-over-year increase in total revenue to $9.8 million. This growth was primarily driven by a surge in capital equipment sales, which rose to $5.7 million from $1.2 million in the prior year's quarter. The company also saw improved gross margins of 78%, up from 74% in Q3 2025, attributed to favorable product mix and pricing discipline. Despite a net loss of $7.7 million due to increased operating expenses for headcount and commissions, the company demonstrated improved cash management with operating cash use decreasing by 56% sequentially. Management raised full-year revenue guidance to at least $25 million and announced a leadership transition where Richard Fabian will succeed Dr. Arun Menawat as CEO in January 2027.
Topics: financial guidance gross margin net loss revenue growth